IACS-010759 in Advanced Cancers

Inclusion Criteria: * Non-pregnant. * Subjects must have histologically confirmed malignancy that is metastatic or unresectable and for which there is no available therapy likely to convey clinical benefit. * Subjects must have received at least one line of systemic therapy in the advanced/metastatic setting. Subjects with diseases without known effective options are also eligible. a) Subjects with relapsed and/or refractory lymphoma must have had at least 2 prior lines of systemic therapy and are not candidates for high dose therapy/autologous stem cell transplant. * Subjects must have evaluable disease for the dose escalation, and measurable disease for the dose expansion. * Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Subjects must have a life expectancy \>= 12 weeks. * Absolute neutrophil count \>= 1,500/mcL. * Hemoglobin \>= 9 g/dL. * Platelets \>= 100,000/mcL. * Total bilirubin =\< 1.5 x the institutional upper limit of normal (ULN). * Aspartate transaminase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alanine transaminase (ALT) serum glutamic pyruvic transaminase (SGPT) =\< 2.5 x institutional ULN or =\< 5 x institutional ULN in the presence of liver metastases. * Creatinine clearance \>= 45 mL/min/1.73 m\^2 for subjects with creatinine levels above institutional normal. * Women of childbearing potential (WOCBP) must agree to use an adequate method of contraception during the study and until 3 months after the…